Erase calories & lighten up
Obesity and its severe comorbidities remain a major burden for the billions of affected individuals because the current anti-obesity medical therapy is unsatisfactory in terms of efficacy and safety. We aim to develop proprietary first-in-class drugs to treat obesity and its comorbidities based on novel mechanism into pharmaceutical products for the world market. We identified a set of small molecules with remarkable in vivo potency and selectivity i.e. absence of side-effects in two vertebrate models. Currently, we solidify the most promising candidate compounds using pre-clinical obesity models and set herewith the stage for their clinical development.
Josua Jordi, CEO